Lorna Ewart, Athanasia Apostolou, Skyler A. Briggs, et al. Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. Communications Medicine. 2022;2:154. doi:10.1038/s43856-022-00209-1
Dean G. Brown, Heike J. Wobst, Abhijeet Kapoor, Leslie A. Kenna, Noel Southall. Clinical development times for innovative drugs. Nature Reviews Drug Discovery. 2021;21(11):793-794. doi:10.1038/d41573-021-00190-9
Michael Balls. It’s Time to Include Harm to Humans in Harm–Benefit Analysis — But How to Do It, That is the Question. Alternatives to Laboratory Animals. 2021;49(5):182-196. doi:10.1177/02611929211062223
Hubert Dirven, Gunn E. Vist, Sricharan Bandhakavi, et al. Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review. Scientific Reports. 2021;11(1):6403. doi:10.1038/s41598-021-85708-2
Simon Lohse. Scientific inertia in animal-based research in biomedicine. Studies in History and Philosophy of Science Part A. 2021;89:41-51. doi:10.1016/j.shpsa.2021.06.016
Julia M. L. Menon, Merel Ritskes-Hoitinga, Pandora Pound, Erica van Oort. The impact of conducting preclinical systematic reviews on researchers and their research: A mixed method case study. PloS One. 2021;16(12):e0260619. doi:10.1371/journal.pone.0260619
Merel Ritskes-Hoitinga, Cathalijn Leenaars, Wouter Beumer, Tineke Coenen-de Roo, Frans Stafleu, Franck L. B. Meijboom. Improving Translation by Identifying Evidence for More Human-Relevant Preclinical Strategies. Animals: an open access journal from MDPI. 2020;10(7):1170. doi:10.3390/ani10071170